$NUMD
Nu-Med Plus Inc

2023 Q4 Form 10-Q Financial Statement

#000154812323000160 Filed on November 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $55.34K $15.15K $58.02K
YoY Change 766.04% -73.89% -49.86%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $40.00
YoY Change -100.0% -98.49%
% of Gross Profit
Operating Expenses $55.34K $15.15K $58.05K
YoY Change 766.04% -73.91% -50.96%
Operating Profit -$15.15K -$58.05K
YoY Change -73.91% -50.96%
Interest Expense -$1.260K $1.260K
YoY Change 26.0%
% of Operating Profit
Other Income/Expense, Net -$1.260K
YoY Change
Pretax Income -$56.60K -$16.41K -$58.05K
YoY Change -232.83% -71.74% -50.96%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$56.60K -$16.41K -$58.05K
YoY Change -232.83% -71.74% -50.96%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 81.35M shares 81.35M shares 79.35M shares
Diluted Shares Outstanding 81.35M shares 79.74M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.810K $11.09K $630.00
YoY Change -90.7% 1660.32% -98.02%
Cash & Equivalents $6.806K $11.09K $628.00
Short-Term Investments
Other Short-Term Assets $6.650K $2.660K $2.540K
YoY Change 4.72% 4.72% -10.25%
Inventory
Prepaid Expenses $6.650K $2.660K $2.540K
Receivables
Other Receivables
Total Short-Term Assets $13.46K $13.75K $3.168K
YoY Change -83.08% 333.96% -90.86%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $13.46K $13.75K $3.168K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $13.46K $13.75K $3.168K
YoY Change -83.08% 333.96% -93.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.089K $6.585K $59.37K
YoY Change 12.47% -88.91% 54.04%
Accrued Expenses $6.000K $4.740K $144.6K
YoY Change 500.0% -96.72% 74.77%
Deferred Revenue
YoY Change
Short-Term Debt $100.0K $100.0K $0.00
YoY Change 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $160.2K $145.7K $273.3K
YoY Change 12.37% -46.69% 125.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $160.2K $145.7K $273.3K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $160.2K $145.7K $273.3K
YoY Change 12.37% -46.69% 125.4%
SHAREHOLDERS EQUITY
Retained Earnings -$9.825M -$9.768M -$9.742M
YoY Change 1.29% 0.27%
Common Stock $83.55K $81.35K $81.35K
YoY Change 2.7% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$146.8K -$132.0K -$270.1K
YoY Change
Total Liabilities & Shareholders Equity $13.46K $13.75K $3.168K
YoY Change -83.08% 333.96% -93.82%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$56.60K -$16.41K -$58.05K
YoY Change -232.83% -71.74% -50.96%
Depreciation, Depletion And Amortization $0.00 $0.00 $40.00
YoY Change -100.0% -98.49%
Cash From Operating Activities -$4.280K -$18.87K $630.00
YoY Change -82.48% -3095.24% -101.54%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -4.280K -18.87K 630.0
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -4.280K -18.87K 630.0
YoY Change -105.66% -3095.24% -101.54%
FREE CASH FLOW
Cash From Operating Activities -$4.280K -$18.87K $630.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79480337 shares
CY2023Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
usd
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81348469 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81348469 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-54808
dei Entity Registrant Name
EntityRegistrantName
NU-MED PLUS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
UT
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-3672530
dei Entity Address Address Line1
EntityAddressAddressLine1
640 Belle Terre Rd Building 2 E
dei Entity Address City Or Town
EntityAddressCityOrTown
Port Jefferson
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11777
dei City Area Code
CityAreaCode
(631)
dei Local Phone Number
LocalPhoneNumber
403-4337
dei Security12b Title
Security12bTitle
None
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
81348469 shares
CY2023Q3 us-gaap Cash
Cash
11088 usd
CY2022Q4 us-gaap Cash
Cash
73195 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2660 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6350 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
13748 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
79545 usd
CY2023Q3 us-gaap Assets
Assets
13748 usd
CY2022Q4 us-gaap Assets
Assets
79545 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6585 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7192 usd
CY2023Q3 numd Accounts Payable Related Party Current
AccountsPayableRelatedPartyCurrent
34378 usd
CY2022Q4 numd Accounts Payable Related Party Current
AccountsPayableRelatedPartyCurrent
34378 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
100000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
100000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4740 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
145703 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
142570 usd
CY2023Q3 us-gaap Liabilities
Liabilities
145703 usd
CY2022Q4 us-gaap Liabilities
Liabilities
142570 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81348469 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81348469 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81348469 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81348469 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
81349 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
81349 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9555087 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9555087 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9768391 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9699461 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-131955 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-63025 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13748 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79545 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8846 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5702 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21835 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19900 usd
CY2022Q3 us-gaap Salaries And Wages
SalariesAndWages
35000 usd
us-gaap Salaries And Wages
SalariesAndWages
59000 usd
CY2023Q3 numd Operating Lease Rent Expense
OperatingLeaseRentExpense
3300 usd
CY2022Q3 numd Operating Lease Rent Expense
OperatingLeaseRentExpense
1559 usd
numd Operating Lease Rent Expense
OperatingLeaseRentExpense
9900 usd
numd Operating Lease Rent Expense
OperatingLeaseRentExpense
8971 usd
CY2023Q3 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
3000 usd
CY2022Q3 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
15755 usd
us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
33455 usd
us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
85635 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
34 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2267 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
15146 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
58050 usd
us-gaap Operating Expenses
OperatingExpenses
65190 usd
us-gaap Operating Expenses
OperatingExpenses
175773 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15146 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-58050 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-65190 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-175773 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
1260 usd
us-gaap Interest Expense
InterestExpense
3740 usd
CY2023Q3 us-gaap Other Income
OtherIncome
-1260 usd
us-gaap Other Income
OtherIncome
-3740 usd
us-gaap Other Income
OtherIncome
3000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16406 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-58050 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-68930 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-172773 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16406 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-58050 usd
us-gaap Net Income Loss
NetIncomeLoss
-68930 usd
us-gaap Net Income Loss
NetIncomeLoss
-172773 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81348469 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79739773 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81348469 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79480337 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-63025 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-28204 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-91229 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24320 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-115549 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16406 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-131955 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-132358 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-56653 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-189011 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-58070 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-247081 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
35000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-58050 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-270131 usd
us-gaap Net Income Loss
NetIncomeLoss
-68930 usd
us-gaap Net Income Loss
NetIncomeLoss
-172773 usd
us-gaap Depreciation
Depreciation
2266 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
3000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
8222 usd
us-gaap Share Based Compensation
ShareBasedCompensation
35000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3690 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2540 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-8222 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-607 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31622 usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
43378 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3740 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
52000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62107 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14047 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-62107 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11047 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73195 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11675 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11088 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
628 usd
CY2022 us-gaap Gain Loss On Sale Of Properties
GainLossOnSaleOfProperties
3000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Revenue Recognition Allowances
RevenueRecognitionAllowances
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">b. Revenue Recognition</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Financial Accounting Standards Board (“FASB”) issued new guidance for the recognizing and reporting of revenue in contracts with customers. The effective date for implementation for public companies was January 1, 2018.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The new guidance established a five-step analysis to be followed when determining the recognition of revenue.</p><table cellpadding="0" cellspacing="0" style="font: 12pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-size: 10pt">1.</span></td><td><span style="font-size: 10pt">Identify the contract with a customer.</span></td></tr></table><table cellpadding="0" cellspacing="0" style="font: 12pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-size: 10pt">2.</span></td><td><span style="font-size: 10pt">Identify the performance obligations in the contract.</span></td></tr></table><table cellpadding="0" cellspacing="0" style="font: 12pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-size: 10pt">3.</span></td><td><span style="font-size: 10pt">Determine the transaction price.</span></td></tr></table><table cellpadding="0" cellspacing="0" style="font: 12pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-size: 10pt">4.</span></td><td><span style="font-size: 10pt">Allocate the transaction price to the performance obligations in the contract.</span></td></tr></table><table cellpadding="0" cellspacing="0" style="font: 12pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-size: 10pt">5.</span></td><td><span style="font-size: 10pt">Recognize revenue when, or as, the reporting organization satisfied a performance obligation.</span></td></tr></table><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0">While the Company is an early-stage company with no revenue, at the time we begin to generate revenue the Company will recognize such revenue in conformity with the guidelines set forth by ASC 606.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">c. Estimates</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</p>
us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
500 usd
us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
0 shares
us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
0 shares
numd Dilutive Shares
DilutiveShares
0 shares
numd Dilutive Shares
DilutiveShares
0 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">h. Concentrations and Credit Risk <b><i>- </i></b>The Company has relied on a small group of investors to fund its operations. If this group becomes unable or unwilling to provide additional funding, the Company may be unable to remain in business or to execute on its business plan.</p>
us-gaap Depreciation
Depreciation
usd
numd Planned Expenditures
PlannedExpenditures
1200000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
83893 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
90368 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
83893 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
90368 usd
us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
0 usd
us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
2267 usd
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
3000 usd
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81348469 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81348469 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81348469 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81348469 shares
CY2022Q3 numd Monthly Office Lease Payment
MonthlyOfficeLeasePayment
1059 usd
CY2023Q3 numd Monthly Office Lease Payment
MonthlyOfficeLeasePayment
1000 usd
us-gaap Other Expenses
OtherExpenses
500 usd
CY2023Q3 us-gaap Salaries And Wages
SalariesAndWages
usd
us-gaap Salaries And Wages
SalariesAndWages
usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
usd
CY2023Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
CY2022Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
usd
us-gaap Interest Expense
InterestExpense
usd
CY2022Q3 us-gaap Other Income
OtherIncome
usd
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79739773 shares
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
usd
us-gaap Increase Decrease In Notes Payable Related Parties
IncreaseDecreaseInNotesPayableRelatedParties
usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
usd
CY2023Q3 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
usd
CY2022Q4 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
usd
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001543637

Files In Submission

Name View Source Status
0001548123-23-000160-index-headers.html Edgar Link pending
0001548123-23-000160-index.html Edgar Link pending
0001548123-23-000160.txt Edgar Link pending
0001548123-23-000160-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
numd-20230930.htm Edgar Link pending
numd-20230930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
numd-20230930_cal.xml Edgar Link unprocessable
numd-20230930_def.xml Edgar Link unprocessable
numd-20230930_pre.xml Edgar Link unprocessable
numd-20230930_lab.xml Edgar Link unprocessable
numd-20230930_htm.xml Edgar Link completed